Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

112 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Metastatic castration-resistant prostate cancer and PARP inhibitors: From tumor genomics to new therapeutic combinations].
Oudard S, Timsit MO, Maillet D, Mouillet G, Campedel L, Colomba É, Dourthe LM, Eymard JC, Gobert A, Jamet C, Joly C, Serrate C, Ploussard G. Oudard S, et al. Among authors: eymard jc. Bull Cancer. 2024 Sep 3:S0007-4551(24)00254-6. doi: 10.1016/j.bulcan.2024.05.008. Online ahead of print. Bull Cancer. 2024. PMID: 39232886 Free article. Review. French.
[Cell therapy and prostate cancer].
Eymard JC, Bernard J. Eymard JC, et al. Bull Cancer. 2003 Aug-Sep;90(8-9):734-43. Bull Cancer. 2003. PMID: 14609763 Free article. Review. French.
Combining docetaxel with estramustine: back to the future?
Oudard S, Eymard JC, Fizazi K. Oudard S, et al. Among authors: eymard jc. J Clin Oncol. 2009 Mar 1;27(7):1148-9; author reply 1149-50. doi: 10.1200/JCO.2009.21.2274. Epub 2009 Jan 26. J Clin Oncol. 2009. PMID: 19171697 No abstract available.
Clinical benefits of non-taxane chemotherapies in unselected patients with symptomatic metastatic castration-resistant prostate cancer after docetaxel: the GETUG-P02 study.
Joly F, Delva R, Mourey L, Sevin E, Bompas E, Vedrine L, Ravaud A, Eymard JC, Tubiana-Mathieu N, Linassier C, Houede N, Guillot A, Ringensen F, Cojocarasu O, Valenza B, Leconte A, Lheureux S, Clarisse B, Oudard S. Joly F, et al. Among authors: eymard jc. BJU Int. 2015 Jan;115(1):65-73. doi: 10.1111/bju.12552. BJU Int. 2015. PMID: 24180479 Clinical Trial.
Patients' self-assessment versus investigators' evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15).
Gravis G, Marino P, Joly F, Oudard S, Priou F, Esterni B, Latorzeff I, Delva R, Krakowski I, Laguerre B, Rolland F, Théodore C, Deplanque G, Ferrero JM, Pouessel D, Mourey L, Beuzeboc P, Zanetta S, Habibian M, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Labourey JL, Machiels JP, El Kouri C, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Soulie M, Fizazi K. Gravis G, et al. Among authors: eymard jc. Eur J Cancer. 2014 Mar;50(5):953-62. doi: 10.1016/j.ejca.2013.11.034. Epub 2014 Jan 11. Eur J Cancer. 2014. PMID: 24424105 Clinical Trial.
Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model.
Gravis G, Boher JM, Fizazi K, Joly F, Priou F, Marino P, Latorzeff I, Delva R, Krakowski I, Laguerre B, Walz J, Rolland F, Théodore C, Deplanque G, Ferrero JM, Pouessel D, Mourey L, Beuzeboc P, Zanetta S, Habibian M, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Labourey JL, Machiels JP, El Kouri C, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Soulie M, Oudard S. Gravis G, et al. Among authors: eymard jc. Eur Urol. 2015 Aug;68(2):196-204. doi: 10.1016/j.eururo.2014.09.022. Epub 2014 Sep 30. Eur Urol. 2015. PMID: 25277272 Clinical Trial.
Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P, Gravis G, Foulon S, Joly F, Oudard S, Priou F, Latorzeff I, Mourey L, Soulié M, Delva R, Krakowski I, Laguerre B, Théodore C, Ferrero JM, Beuzeboc P, Habibian M, Rolland F, Deplanque G, Pouessel D, Zanetta S, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Tubiana-Mathieu N, Machiels JP, Kouri CE, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Culine S, Boher JM, Tergemina-Clain G, Legoupil C, Fizazi K. Lavaud P, et al. Among authors: eymard jc. Eur Urol. 2018 May;73(5):696-703. doi: 10.1016/j.eururo.2017.09.022. Epub 2017 Oct 23. Eur Urol. 2018. PMID: 29074061 Clinical Trial.
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.
Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, Lopez-Gitlitz A, Trudel GC, Espina BM, Shu Y, Park YC, Rackoff WR, Yu MK, Small EJ; SPARTAN Investigators. Smith MR, et al. N Engl J Med. 2018 Apr 12;378(15):1408-1418. doi: 10.1056/NEJMoa1715546. Epub 2018 Feb 8. N Engl J Med. 2018. PMID: 29420164 Free article. Clinical Trial.
112 results